Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCL2q
- Development stage
- Preclinical
- Lead developer
- University of Louisville
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
BCL2q is a synthetic G-quadruplex-forming oligonucleotide designed to target and downregulate the expression of the B-cell lymphoma 2 (BCL2) gene. It is based on a highly conserved 25-nucleotide G-rich sequence located in the 5' untranslated region (5' UTR) of the human BCL2 mRNA, which has the potential to fold into a stable RNA G-quadruplex structure. In preclinical research, BCL2q has been evaluated for its ability to inhibit cell proliferation and induce apoptosis in various cancer cell lines, including triple-negative breast cancer (TNBC) cells such as MDA-MB-231, by suppressing BCL2 translation.
- Other names
- BCL2QBCL-2QBCL 2QBCL2Q oligonucleotideBCL-2Q oligonucleotideBCL 2Q oligonucleotide
Beyond the preview
Go deeper on BCL2q.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCL2q.